Biofil Chemicals & Pharmaceuticals

BSE: BIOFILCHEM524396ISIN INE829A01014

Healthcare
Pharmaceuticals

BSE listing

Share price

₹32.86-0.13 (-0.39%)

as of 18 Sep 2026

52W high: ₹46.82
52W low: ₹25.60
Off 52W high: -29.82%
1M return: +5.46%
3M return: -7.31%
6M return: +9.61%
1Y return: -24.98%
20D avg volume: 49,309
50 DMA: ₹32.67
200 DMA: ₹33.32

Key ratios Standalone

Market cap: ₹53.48 Cr
Current price: ₹32.86
52W high / low: ₹46.82 / ₹25.60
Face value: ₹10.00
P/E: 109.53
P/B: 2.91
EPS (TTM): ₹0.30
Book value / share: ₹11.29
ROE: 2.63%
ROCE: 15.60%
Operating margin: 1.64%
Net margin: 0.88%
Debt / equity: 0.14
Net debt: ₹2.96 Cr
Interest cover: 346.00
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 186.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	12.35	7.57	0.86	13.54	6.43	8.35	—
	0.06	0.11	0.08	0.06	2.83	0.24	—
	12.28	7.21	0.83	13.49	6.50	8.33	—
	9.48	1.80	3.23	1.18	1.17	2.08	—
	3.12	1.95	0.00	7.07	9.74	5.26	—
	0.19	0.22	0.19	0.18	0.21	0.25	—
	0.00	0.00	0.00	0.00	0.01	0.01	—
	0.07	0.07	0.07	0.07	0.07	0.08	—
	0.23	0.33	0.22	0.15	0.28	0.34	—
	0.13	0.47	0.11	0.11	2.76	0.25	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.13	0.47	0.11	0.11	2.76	0.25	—
	0.03	0.26	0.03	0.03	0.35	0.05	—
	0.11	0.21	0.08	0.08	2.41	0.20	—
	0.07	0.13	0.05	0.05	1.48	0.12	—
Key metrics
	0.20	0.54	0.18	0.18	2.84	0.34	—
	1.60%	7.10%	20.90%	1.30%	44.20%	4.10%	—
	0.90%	2.80%	9.30%	0.60%	37.50%	2.40%	—
	—	2.10%	—	0.50%	—	1.40%	—
	92.10%	-9.30%	—	—	—	—	—
	-95.40%	5.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	34.32	28.40	33.40	—
	0.31	3.08	0.31	—
	33.81	28.03	32.97	—
	15.69	7.38	5.31	—
	12.14	18.77	26.32	—
	0.78	0.80	0.79	—
	0.00	0.01	0.04	—
	0.28	0.27	0.38	—
	0.93	0.99	0.92	—
	0.82	3.45	0.74	—
	0.00	0.00	0.00	—
	0.82	3.45	0.74	—
	0.35	0.66	0.18	—
	0.48	2.79	0.56	—
	0.30	1.71	0.34	—
Key metrics
	1.10	3.73	1.16	—
	3.21%	13.10%	3.50%	—
	1.40%	9.80%	1.70%	—
	—	15.60%	4.10%	—
	—	-15.00%	—	—
	—	398.20%	—	—
	—	-0.80	-2.02	—
	—	-0.22	-3.43	—
	—	0.14	0.03	—
	—	2.96	0.34	—
	—	186.7	116.5	—
Balance sheet
	—	42.85	50.96	—
	—	35.86	42.55	—
	—	0.06	0.13	—
	—	27.59	38.31	—
	—	4.00	3.34	—
	—	0.95	—	—
	—	6.93	8.34	—
	—	17.06	30.99	—
	—	20.69	31.85	—
	—	3.02	0.47	—
	—	3.02	0.47	—
	—	0.00	0.00	—
	—	21.56	18.78	—
Cash flow
	—	-0.60	-1.92	—
	—	1.14	-0.10	—
	—	2.54	0.00	—
	—	0.20	0.10	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 46.80%

Holder	Type	Holding	Previous	Change
SCOPE FINANCE COMPANY PRIVATE LIMITED	Promoter Group	13.90%	—	—
MID (INDIA) PHARMACEUTICALS PVT LTD	Promoter Group	7.22%	—	—
STARLINE EQUIFIN PRIVATE LIMITED	Public	7.07%	—	—
CYANO FINANCE AND SALES PVT. LTD.	Promoter Group	5.39%	—	—
MEENA SHAH	Promoter	4.06%	—	—
NIYATI SHAH	Promoter	4.05%	—	—
KETAN SHAH	Promoter	3.03%	—	—
SANDEEP SHAH	Promoter	2.60%	—	—
ROMIL SHAH	Promoter Group	2.35%	—	—
KSL AND INDUSTRIES LIMITED	Public	1.89%	—	—
KISHOR HIMMATSINH JHALA	Public	1.22%	—	—
SMITESH SANALAL SHAH	Promoter	1.15%	—	—
GOM INDUSTRIES LTD	Public	1.11%	—	—
TRUPTI SHAH	Promoter Group	0.63%	—	—
RITU SHAH	Promoter Group	0.55%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Pursuant to Regulation 30, 44 and 47 of SEBI(LODR) Regulations, 2015 and in compliance with Section 108 of the Companies Act, 2013 read with rule 20 of Companies (Management and Administration) ....28 Aug 2026 · Company Update / Newspaper Publication
Information under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 108 of the Companies Act, 2013 regarding voting through electronic ....26 Aug 2026 · AGM/EGM / AGM
Intimation for Dispatch of letter to those shareholders whose e-mail addresses are not registered with company/ registrar and share transfer agent/ depository participants26 Aug 2026 · Company Update / General
Submission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure ....26 Aug 2026 · Others / Reg. 34 (1) Annual Report
Submission of Notice of 41st AGM scheduled to be held on Wednesday 23rd September 2026 at 3:00 P.M. (IST) through video conferencing (VC)/ Other audio-visual means (OAVM)26 Aug 2026 · AGM/EGM / AGM
Newspaper publication of Notice of 41st AGM through Video Conferencing (''''VC'''')/ Other Audio Visual Means (''''OAVM'''')19 Aug 2026 · Company Update / Newspaper Publication
Submission of publication of Un-audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 201512 Aug 2026 · Company Update / Newspaper Publication
Continuation of Directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-executive Independent Director of the company, notwithstanding his attaining the age of 75 (Seventy Five )Years11 Aug 2026 · Company Update / Change in Management
Un-Audited Financial Results for the quarter ended 30th June 202611 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on Tuesday 11th August, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited ....1 Aug 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.1 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the quarter ended 30.06.202625 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Submission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 20151 Jun 2026 · Company Update / Newspaper Publication
Audited Financial Result for the Financial Year ended 31.03.202630 May 2026 · Result / Financial Results
Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.30 May 2026 · Board Meeting / Outcome of Board Meeting
Submission of Annual Secretarial Compliance Report for the Financial year ended 31st March 202623 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited ....21 May 2026 · Board Meeting / Board Meeting
The Company hereby submit drafts intimation letter sent to holders of Physical shares of the company for updating PAN, KYC, Nomination and other details in accordance with applicable SEBI ....5 May 2026 · Company Update / General
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....10 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Submission of Publication in Newspaper pursuant to SEBI circular for Special Window for Transfer and Dematerialisation of Physcial Securities.3 Apr 2026 · Company Update / Newspaper Publication
Intimation regarding SEBI Circular dated January 30, 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .2 Apr 2026 · Company Update / General
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended on 31st March, 20261 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window period for the quarter and financial year ended 31.03.202624 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Submission of Publication of Un-audited Financial Results for the quarter and nine months ended on 31st December 2025 in the newspaper pursuant to Regulation 47 of SEBI( Listing Obligation ....14 Feb 2026 · Company Update / Newspaper Publication
Un-Audited Financial Results of the Company for the quarter and nine month ended on 31st December, 202513 Feb 2026 · Result / Financial Results
Outcome of Board Meeting held on Friday 13th February, 202613 Feb 2026 · Board Meeting / Outcome of Board Meeting
Clarification on Price Movement3 Feb 2026 · Company Update / General
The Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Ltd on February 3, 2026 with reference to significant movement in price, in order to ensure that investors ....3 Feb 2026 · Company Update / Clarification
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1. the Un-Audited ....3 Feb 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended on 31st December,20252 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading window with effect from Thursday 01st January, 2026.23 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Receipt of Fine from BSE Limited3 Dec 2025 · Company Update / General
Receipt of Fine from National Stock Exchange.26 Nov 2025 · Company Update / General
Submission of Publication of Un-audited Financial Result in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 201515 Nov 2025 · Company Update / Newspaper Publication
To review, consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with Limited Review Report13 Nov 2025 · Board Meeting / Outcome of Board Meeting
To review, consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with Limited Review Report13 Nov 2025 · Result / Financial Results
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve To consider ....7 Nov 2025 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended on 30th September, 2025.4 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading Window with effect from Wednesday 01st October, 202529 Sep 2025 · Insider Trading / SAST / Closure of Trading Window

Board meetings

11 Aug 2026 Board Meeting - Financial Results